Tonix Pharmaceuticals — Third Quarter 2026 Earnings Summary

Tonix Pharmaceuticals reported third-quarter 2026 net product revenue of approximately $17.2 million, driven by $15.0 million in TONMYA sales which represented a 37% increase from the second quarter. The company expanded its commercial reach with payer coverage now totaling approximately 166 million lives and completed a sales force expansion to 150 representatives in September 2026. As of September 30, 2026, Tonix held $163 million in cash and cash equivalents, with a net loss for the quarter of $53.3 million. The company also announced the initiation of several clinical programs, including a Phase 2 study for TNX-102 SL in major depressive disorder and a Phase 2 field study for TNX-4800 in Lyme disease prevention.